Delivering more actionable and strategically valuable research, The Business Research Company’s 2026 market reports feature market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights.
Blood Plasma Derivatives Market Value Analysis: What Growth Is Expected Over The Forecast Period?
The market for blood plasma derivatives has experienced substantial expansion recently, projecting a climb from $55.76 billion in 2025 to $60.76 billion in 2026, reflecting a 9.0% compound annual growth rate. This upward trajectory during the past period has been fueled by several key factors: a rise in the identification of infrequent blood conditions, the broader implementation of plasma donation initiatives, an escalating need for albumin-based treatments, advancements in the methods used to separate plasma components, and an increased utilization of plasma within healthcare facilities.
The sector for blood plasma derivatives is poised for substantial expansion over the upcoming years, projecting an increase to $86.68 billion by the year 2030, driven by a compound annual growth rate (CAGR) of 9.3%. This predicted growth trajectory is fueled by several key factors, including a heightened incidence of immunodeficiency disorders, augmented financial commitments towards therapies developed from plasma, the broadening of international networks for plasma donation, a greater emphasis on achieving self-sufficiency in plasma provisions, and significant progress in recombinant protein technologies. Key developments anticipated during this forecast period encompass a mounting demand for therapies utilizing immunoglobulins, increased acceptance of recombinant plasma-based treatments, advancements in technologies for fractionating and purifying plasma components, a stronger concentration on processes aimed at reducing pathogens, and improvements in the efficiency of cold chain management and plasma processing.
Download A Free Sample Report For Comprehensive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=12107&type=smp
Blood Plasma Derivatives Market Development Factors: Which Trends Are Supporting Demand?
The escalating incidence of hemophilia is anticipated to be a significant factor propelling the expansion of the blood plasma derivatives market. Hemophilia, an inherited disorder characterized by impaired blood clotting, can lead to spontaneous hemorrhages as well as excessive bleeding subsequent to trauma or surgical procedures. For individuals experiencing congenital or acquired hemostasis dysfunctions, therapeutic agents derived from blood plasma offer a potent means to enhance blood clotting capabilities. Specifically, hemophilia A, von Willebrand disease, and hemophilia B are managed through the administration of factor VIII, factor VIII/vWF, and factor IX concentrates, respectively. Supporting this trend, the World Federation of Hemophilia (WFH) Annual Global Survey (AGS) reported in October 2025, with data from 2024, indicating a 6% increase globally in the diagnosis of hemophilia cases, a corresponding 6% rise in identified von Willebrand disease cases, and a notable 9% surge in the identification of other inherited bleeding disorders. Consequently, the growing prevalence of hemophilia is a key contributor to the expanding blood plasma derivatives market.
Blood Plasma Derivatives Market Segments: Where Are The Largest Growth Opportunities?
The blood plasma derivatives market covered in this report is segmented –
1) By Type: Albumin, Factor VIII, Factor IX, Immunoglobulin, Hyperimmune Globulin, Other Types
2) By Application: Hemophilia, Hypogammaglobulinemia, Immunodeficiency Diseases, Von Willebrand’s Disease, Other Applications
3) By End-User: Hospitals, Clinics, Other End-Users
Subsegments:
1) By Albumin: Human Serum Albumin, Recombinant Albumin
2) By Factor VIII: Plasma-Derived Factor VIII, Recombinant Factor VIII
3) By Factor IX: Plasma-Derived Factor IX, Recombinant Factor IX
4) By Immunoglobulin: Intravenous Immunoglobulin (IVIG), Subcutaneous Immunoglobulin (SCIG)
5) By Hyperimmune Globulin: Specific Pathogen-Reduced Hyperimmune Globulin, Standard Hyperimmune Globulin
6) By Other Types: Fibrinogen, Clotting Factor Concentrates, Plasma-Derived Proteins
Blood Plasma Derivatives Market Transformation Trends: Which Innovations Are Driving Change?
Within the blood plasma derivatives industry, leading corporations are prioritizing advancements in their supply chains, notably through the development of intravenous immunoglobulin (IVIg). This therapeutic agent functions by furnishing patients experiencing immunodeficiency with essential antibodies, thereby bolstering their immune systems. IVIg is essentially a medicinal product composed of antibodies purified from the plasma of a vast number of healthy individuals, aimed at regulating immune responses. As an illustration, in August of 2025, Octapharma, a company headquartered in Switzerland renowned for its human protein products, unveiled Gamten 10% IVIg through the UK Plasma for Medicines Programme. This particular IVIg formulation, derived from plasma donated by individuals in the UK, is intended to deliver immunoglobulin replacement therapy to patients suffering from either primary or secondary immunodeficiency, while the company also provides specialized treatments for coagulation disorders and critical care needs.
Blood Plasma Derivatives Market Major Participants And Competitive Dynamics
Major companies operating in the blood plasma derivatives market are Bayer AG, Sanofi S.A., Takeda Pharmaceutical Company Limited, Baxter International Inc., CSL Limited, Meiji Group, Grifols S.A., Shire Pharmaceuticals Inc., GC Biopharma Corp, Emergent BioSolutions Inc., Shanghai Raas Blood Products Co Ltd., Kedrion S.p.A., Sanquin, Biotest AG, Bio Products Ltd., ADMA Biologics Inc., China Biologic Products Holdings Inc., BioIVT, PlasmaGen BioSciences Pvt. Ltd., Virchow Biotech Private Limited, LFB S.A., Intas Pharmaceuticals Ltd., Octapharma Plasma
Access The Complete Blood Plasma Derivatives Market Report:
https://www.thebusinessresearchcompany.com/report/blood-plasma-derivatives-global-market-report
Blood Plasma Derivatives Market Largest Region By Revenue And Market Share
North America was the largest region in the blood plasma derivatives market in 2025. The regions covered in the blood plasma derivatives market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model